{"entity":{"id":"eb-nk-301","kind":"drug","name":"EB-NK-301","aka":["TROP2-CAR NK"],"tldr":"EB-NK-301 is an experimental donor-derived immune-cell therapy aimed at TROP2. Its registered trial combines phase 1 and phase 2 testing; no clinical benefit is established.","summary":"EB-NK-301 is an allogeneic TROP2 CAR-NK product in NCT07589530, a recruiting phase 1/2 study. The registry plans 60 participants and marks the March 2, 2026 start as actual. Primary completion is estimated for February 14, 2027; the record was last updated May 15, 2026. No tabular results are posted. The combined phase 1/2 designation does not establish completed phase 2 efficacy or postoperative TNBC benefit.","status":"phase-1","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07589530","url":"https://clinicaltrials.gov/study/NCT07589530"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":["car-nk-macrophage"],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07589530"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"CAR-NK cell therapy","mechanism":"CAR-NK cell therapy directed at TROP2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/eb-nk-301/","neighbours":{"technology":[{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"trial":[{"id":"nct07589530","kind":"trial","name":"Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors","route":"/trials/nct07589530/"}]}}